Literature DB >> 17139902

Prognostic value of thymidylate synthase, epidermal growth factor receptors and vascular endothelial growth factor in patients with stage III colon cancer.

Dino Tarabar1, Slavica Knezević-Usaj, Zoran Petrović, Dusan Jovanović, Radoje Doder.   

Abstract

PURPOSE: We studied the prognostic value of thymidylate synthase (TS), Epidermal Growth Factor Receptors (EGFR) and Vascular Endothelial Growth Factor (VEGF) expression in primary colon cancer (CC). PATIENTS AND METHODS: Those three markers were immunohistochemically assessed on tumour sections from 100 patients with CC Dukes C. All patients received the same adjuvant chemotherapy with FU/Leukovocin according to Mayo protocol. Considering the clinical course they were classified in two groups: bad in which all patients progressed and good in which neither progressed during the five year follow up period.
RESULTS: TS, EGFR and VEGF were an independent prognostic factor for time to progression (TTP) and overall survival (OS). Findings of at least two maximum expressed investigated markers, significantly increases the risk of progression which influences shorter five year survival, and the single maximum expression does not necessarily have to be a bad prognostic sign.
CONCLUSION: Highest expression of TS, EGFR and VEGF carries prognostic significance with respect to TTP and OS for patients with Dukes C colon cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17139902     DOI: 10.2298/aci0602143t

Source DB:  PubMed          Journal:  Acta Chir Iugosl        ISSN: 0354-950X


  2 in total

1.  Polymorphism of thymidylate synthase gene associated with its protein expression in human colon cancer.

Authors:  Kai-Huan Yu; Wei-Xing Wang; You-Ming Ding; Hui Li; Ze-Sheng Wang
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

2.  Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.

Authors:  Jinsong Li; Huayun Deng; Meichun Hu; Yuanzhang Fang; Amanda Vaughn; Xiaopan Cai; Leqin Xu; Wei Wan; Zhenxi Li; Shijie Chen; Xinghai Yang; Song Wu; Jianru Xiao
Journal:  Oncotarget       Date:  2015-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.